S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?

Cytokinetics (CYTK) Stock Price, News & Analysis

$71.41
+0.26 (+0.37%)
(As of 03/27/2024 ET)
Today's Range
$69.88
$73.18
50-Day Range
$63.75
$84.80
52-Week Range
$25.98
$110.25
Volume
2.48 million shs
Average Volume
3.54 million shs
Market Capitalization
$7.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$77.00

Cytokinetics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.87 Rating Score
Upside/​Downside
7.8% Upside
$77.00 Price Target
Short Interest
Bearish
14.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.94
Upright™ Environmental Score
News Sentiment
0.82mentions of Cytokinetics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$10.04 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.51) to ($3.18) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.37 out of 5 stars

Medical Sector

324th out of 939 stocks

Pharmaceutical Preparations Industry

145th out of 422 stocks

CYTK stock logo

About Cytokinetics Stock (NASDAQ:CYTK)

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

CYTK Stock Price History

CYTK Stock News Headlines

[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
7 Biotech Stocks Ready to Ride the Sector's Resurgence
CYTK Mar 2024 63.000 call
CYTK Mar 2024 69.000 put
CYTK Mar 2024 69.000 call
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
CYTK Mar 2024 62.000 call
CYTK Apr 2024 58.000 put
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
CYTK Aug 2024 30.000 put
CYTK Mar 2024 61.000 put
Q4 2023 CytomX Therapeutics Inc Earnings Call
CYTK Apr 2024 65.000 put
CYTK Apr 2024 110.000 call
CYTK Apr 2024 73.000 call
CYTK Apr 2024 72.000 put
CYTK Mar 2024 83.500 call
CYTK Mar 2024 72.000 put
CYTK Mar 2024 68.000 call
See More Headlines
Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CYTK
Employees
423
Year Founded
1997

Price Target and Rating

Average Stock Price Target
$77.00
High Stock Price Target
$108.00
Low Stock Price Target
$42.00
Potential Upside/Downside
+7.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.87
Research Coverage
15 Analysts

Profitability

Net Income
$-526,240,000.00
Net Margins
-6,988.63%
Pretax Margin
-6,988.63%

Debt

Sales & Book Value

Annual Sales
$7.53 million
Book Value
($3.94) per share

Miscellaneous

Free Float
99,091,000
Market Cap
$7.36 billion
Optionable
Optionable
Beta
0.69

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Robert I. BlumMr. Robert I. Blum (Age 60)
    CEO, President & Director
    Comp: $1.14M
  • Mr. Robert C. WongMr. Robert C. Wong (Age 56)
    VP & Chief Accounting Officer
    Comp: $463.75k
  • Dr. Fady Ibraham Malik FACC (Age 60)
    M.D., Ph.D., Executive Vice President of Research & Development
    Comp: $776.99k
  • Mr. Andrew M. Callos (Age 68)
    Executive VP & Chief Commercial Officer
    Comp: $745.4k
  • Dr. James A. Spudich Ph.D. (Age 82)
    Co-Founder & Member of Scientific Advisory Board
    Comp: $21.94k
  • Mr. Jeff Lotz
    Vice President of Sales & Operations
  • Mr. Matt Yang
    Vice President of Corporate Finance and Financial Planning & Analysis
  • Mr. Steven M. Cook (Age 65)
    Senior Vice President of Supply Chain Operations & Technical Operations
  • Ms. Diane Weiser
    Senior Vice President of Corporate Communications & Investor Relations
  • Ms. Kari K. Loeser J.D.
    VP & Chief Compliance Officer

CYTK Stock Analysis - Frequently Asked Questions

Should I buy or sell Cytokinetics stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CYTK shares.
View CYTK analyst ratings
or view top-rated stocks.

What is Cytokinetics' stock price target for 2024?

15 Wall Street research analysts have issued 1 year target prices for Cytokinetics' stock. Their CYTK share price targets range from $42.00 to $108.00. On average, they anticipate the company's stock price to reach $77.00 in the next year. This suggests a possible upside of 7.8% from the stock's current price.
View analysts price targets for CYTK
or view top-rated stocks among Wall Street analysts.

How have CYTK shares performed in 2024?

Cytokinetics' stock was trading at $83.49 at the beginning of the year. Since then, CYTK shares have decreased by 14.5% and is now trading at $71.41.
View the best growth stocks for 2024 here
.

When is Cytokinetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CYTK earnings forecast
.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) released its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($1.03) by $0.35. The biopharmaceutical company earned $1.70 million during the quarter, compared to the consensus estimate of $7.62 million. Cytokinetics's revenue was down 10.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.45) EPS.

What guidance has Cytokinetics issued on next quarter's earnings?

Cytokinetics updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.0 million-$5.0 million, compared to the consensus revenue estimate of $28.5 million.

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (11.24%), Vanguard Group Inc. (10.70%), Price T Rowe Associates Inc. MD (3.31%), RTW Investments LP (2.58%), Northern Trust Corp (1.08%) and First Turn Management LLC (0.82%). Insiders that own company stock include B Lynne Parshall, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Muna Bhanji, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Sandford D Smith, Santo J Costa and Wendall Wierenga.
View institutional ownership trends
.

How do I buy shares of Cytokinetics?

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CYTK) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners